We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+24.51%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.93B
AUM Growth
-$596M
Cap. Flow
-$803M
Cap. Flow %
-41.67%
Top 10 Hldgs %
67.29%
Holding
46
New
–
Increased
6
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$18.9M
2
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$8.84M
3
GNCA
Genocea Biosciences, Inc.
GNCA
+$6.15M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$2.42M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$1.04M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$774M
2
ESTC icon
Elastic
ESTC
+$66.1M

Sector Composition

Rank Sector Weight
1 Healthcare 73.01%
2 Technology 23.61%
3 Industrials 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESTC icon
1
Elastic
ESTC
$6.7B
$444M 23.07%
5,562,153
-791,345
-12% -$66.1M
RARX
2
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$138M 7.14%
6,138,797
– –
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$7.31B
$135M 6.99%
4,912,306
– –
CBIO
4
Crescent Biopharma
CBIO
$546M
$113M 5.88%
90,890
– –
ALLK
5
DELISTED
Allakos
ALLK
$91.9M 4.77%
2,268,188
– –
EPZM
6
DELISTED
Epizyme, Inc
EPZM
$85.2M 4.42%
6,877,518
– –
SENS icon
7
Senseonics Holdings Inc
SENS
$254M
$75.7M 3.93%
1,544,413
– –
CRSP icon
8
CRISPR Therapeutics
CRSP
$4.69B
$74.7M 3.88%
2,090,678
– –
CMTA
9
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$70.7M 3.67%
2,707,734
– –
ADAP
10
DELISTED
Adaptimmune Therapeutics
ADAP
$68.1M 3.53%
15,832,611
– –
MRSN
11
DELISTED
Mersana Therapeutics
MRSN
$62.6M 3.25%
475,771
+150,000
+46% +$18.9M
OBSV
12
DELISTED
ObsEva SA Ordinary Shares
OBSV
$58.7M 3.05%
4,586,563
– –
DERM
13
DELISTED
Dermira, Inc.
DERM
$47.5M 2.47%
3,506,649
– –
ARDX icon
14
Ardelyx
ARDX
$1.24B
$42.9M 2.23%
15,335,047
– –
AUPH icon
15
Aurinia Pharmaceuticals
AUPH
$1.95B
$33.6M 1.75%
5,172,683
+364,200
+8% +$2.42M
MRKR icon
16
Marker Therapeutics
MRKR
$18.5M
$33M 1.71%
500,000
– –
SYBX
17
DELISTED
Synlogic
SYBX
$32.1M 1.67%
281,961
– –
NITE
18
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
$30.8M 1.6%
1,214,285
+500,000
+70% +$8.84M
LQDA icon
19
Liquidia Corp
LQDA
$7.72B
$28.3M 1.47%
2,486,062
– –
TPST icon
20
Tempest Therapeutics
TPST
$14.3M
$26.5M 1.38%
9,060
– –
AFMD
21
DELISTED
Affimed
AFMD
$21.6M 1.12%
513,889
– –
SBBP
22
DELISTED
Strongbridge Biopharma plc.
SBBP
$20.6M 1.07%
4,141,308
– –
GNCA
23
DELISTED
Genocea Biosciences, Inc.
GNCA
$20.6M 1.07%
4,368,534
+1,243,534
+40% +$6.15M
LITS
24
Lite Strategy Inc
LITS
$32.4M
$17.6M 0.91%
286,029
– –
AVEO
25
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$17.1M 0.89%
2,089,604
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q1 2019 Portfolio in Review

As of Q1 2019, NEA Management Company held 46 positions worth $1.93B, down 24% from $2.52B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

NEA Management Company withdrew a net $803M in Q1 2019, closing 1 position and reducing 1 holding. Its most notable exit was TESARO, Inc., an estimated $774M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 80% a quarter earlier, followed by Technology and Industrials.

Against the trend, NEA Management Company added an estimated $18.9M to Mersana Therapeutics.

  • NEA Management Company added most to Mersana Therapeutics in Q1 2019, an estimated $18.9M increase.
  • NEA Management Company's biggest Q1 2019 reduction was Elastic, cutting an estimated $66.1M.
  • NEA Management Company fully exited TESARO, Inc. in Q1 2019, selling an estimated $774M.
  • NEA Management Company's ten largest holdings make up 67% of its $1.93B portfolio in Q1 2019.
  • NEA Management Company opened 0 new positions and closed 1 in Q1 2019.
  • NEA Management Company's portfolio value fell 24% quarter-over-quarter to $1.93B.

Based on NEA Management Company's 13F filing for Q1 2019, filed 8 May 2019.